Skip to main content

Multiple Myeloma and the Kidney

  • 2132 Accesses

Abstract

RG, a 60-year-old African-American man, presents to your clinic with a 6-week history of fatigue and right hip pain, which he attributes to a fall a few months ago. He has not seen a physician in years because he has felt well. However, he did visit the ER a week ago for his hip pain and labs showed a creatinine of 1.9 mg/dL. He has been taking 800–1,200 mg of ibuprofen daily for the last 2 weeks. His physical examination is notable for pain over the right hip. Laboratory studies show a creatinine of 4.6 mg/dL, calcium of 11 mg/dL, and hemoglobin of 7.2 g/dL. Plain films of the right hip show osteolytic lesions. Urine dipstick is negative for protein.

Keywords

  • Multiple Myeloma
  • Light Chain
  • Autologous Stem Cell Transplantation
  • Amyloid Fibril
  • Fanconi Syndrome

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4614-4454-1_50
  • Chapter length: 11 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   189.00
Price excludes VAT (USA)
  • ISBN: 978-1-4614-4454-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   249.99
Price excludes VAT (USA)
Hardcover Book
USD   349.99
Price excludes VAT (USA)

References

  1. Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Haematol. 2000;111:1035–44.

    PubMed  CrossRef  CAS  Google Scholar 

  2. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–72.

    PubMed  CrossRef  CAS  Google Scholar 

  3. Clamp JR. Some aspects of the first recorded case of multiple myeloma. Lancet. 1967;290:1354–6.

    CrossRef  Google Scholar 

  4. Korngold L, Lipari R. Multiple-myeloma III. The antigenic relationship of BenceJones proteins to normal gammaglobulin and multiple-myeloma serum proteins. Cancer. 1956;9:262–72.

    PubMed  CrossRef  CAS  Google Scholar 

  5. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.

    CrossRef  Google Scholar 

  6. Herrara G. Renal lesions associated with plasma cell dyscrasias, practical approach to diagnosis, new concepts and challenges. Arch Pathol Lab Med. 2009;133:240–67.

    Google Scholar 

  7. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17:2533–45.

    PubMed  CrossRef  Google Scholar 

  8. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–73.

    PubMed  CrossRef  CAS  Google Scholar 

  9. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.

    PubMed  CrossRef  Google Scholar 

  10. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–92.

    PubMed  CAS  Google Scholar 

  11. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412.

    PubMed  CrossRef  Google Scholar 

  12. Kyle RA, Therneau TM, Rajkumar SV. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101:2667–74.

    PubMed  CrossRef  Google Scholar 

  13. US Renal Data System: USRDS 2005 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute Diabetes and Digestive and Kidney Diseases; 2005.

    Google Scholar 

  14. Dimopoulos MA, Terpos E, Chanan-Khan A. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;29:4976–84.

    CrossRef  Google Scholar 

  15. Christensen EI, Brin H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol. 2001;280:F562–73.

    PubMed  CAS  Google Scholar 

  16. Batuman V. Proximal tubular injury in myeloma. In: Herrera GA, editor. The kidney in plasma cell dyscrasias, Contribution to nephrology, vol. 153. Basel: Karger; 2007. p. 87–104.

    CrossRef  Google Scholar 

  17. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845–51.

    PubMed  CrossRef  CAS  Google Scholar 

  18. Monteseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13:1438–45.

    CrossRef  Google Scholar 

  19. Basnayake K, Ying WZ, Wang PX, et al. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol. 2010;21:1165–73.

    PubMed  CrossRef  CAS  Google Scholar 

  20. Merlini G, Pozzi C. Mechanisms of renal damage in plasma cell dyscrasias: an overview. In: Herrera GA, editor. The kidney in plasma cell dyscrasias, Contribution to nephrology, vol. 153. Basel: Karger; 2007. p. 66–86.

    CrossRef  Google Scholar 

  21. Keeling J, Herrera GA. The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. In: Herrera GA, editor. The kidney in plasma cell dyscrasias, Contribution to nephrology, vol. 153. Basel: Karger; 2007. p. 116–34.

    CrossRef  Google Scholar 

  22. Ronco P, Plaisier E, Mougenot B. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1:1342–50.

    PubMed  CrossRef  CAS  Google Scholar 

  23. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84:1322–38.

    PubMed  CrossRef  CAS  Google Scholar 

  24. Westermark P, Benson MD, Buxbaum JN. Amyloid: toward terminology clarification. Amyloid. 2005;12:1–4.

    PubMed  CrossRef  CAS  Google Scholar 

  25. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med. 2000;45:107–37.

    PubMed  CAS  Google Scholar 

  26. Herrera GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patient’s bedside to the research laboratory. Ann Diagn Pathol. 2000;4:174–200.

    PubMed  CrossRef  CAS  Google Scholar 

  27. Dember LM. Light chains, casts, sheets and fibrils: monoclonal immunoglobulin diseases and immunotactoid/fibrillaryglomerulopathy. Clin J Am Soc Nephrol. 2006;1:1320–1.

    PubMed  CrossRef  Google Scholar 

  28. Ganeval D, Noël LH, Preud’homme JL, et al. Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney Int. 1984;26(1):1.

    PubMed  CrossRef  CAS  Google Scholar 

  29. Korbet SM, Schwartz MM, Lewis EJ. Immunotactoidglomerulopathy (fibrillary glomerulonephritis). Clin J Am Soc Nephrol. 2006;1:1351–6.

    PubMed  CrossRef  Google Scholar 

  30. Alpers CE, Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 2008;19:34–7.

    PubMed  CrossRef  Google Scholar 

  31. Dimopoulos MA, Panayiotidis P, Moulopoulos LA. Waldenström’s macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214–26.

    PubMed  CAS  Google Scholar 

  32. Gerz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and waldenström’s macroglobulinemia. J Clin Oncol. 1993;11:914.

    Google Scholar 

  33. Veltman GA, van Veen S, Kluin-Nelemans JC. Renal disease in waldenström’s macroglobulinaemia. Nephrol Dial Transplant. 1997;12:1256.

    PubMed  CrossRef  CAS  Google Scholar 

  34. Penfield JG. Multiple myeloma in end-stage renal disease. Semin Dial. 2006;19:329–34.

    PubMed  CrossRef  Google Scholar 

  35. Levi M, Ellis MA, Berl T. Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system and calcium. J Clin Invest. 1983;71(6):1624.

    PubMed  CrossRef  CAS  Google Scholar 

  36. Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–93.

    PubMed  CrossRef  CAS  Google Scholar 

  37. Dimopoulos M, Kyle R, Fermand JP. Guidelines for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood. Prepublished online February 2, 2011:1–17.

    Google Scholar 

  38. Rajkumar VS, Kyle AK. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1371–82.

    PubMed  CrossRef  Google Scholar 

  39. Katzmann JA, Clark RJ, Abraham RS. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–44.

    PubMed  CAS  Google Scholar 

  40. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol. 2008;141:413–22.

    PubMed  CrossRef  CAS  Google Scholar 

  41. Johnson WJ, Kyle RA, Pineda AA. Treatment of renal failure associated with multiple myeloma. Arch Intern Med. 1990;150:863–9.

    PubMed  CrossRef  CAS  Google Scholar 

  42. Zuchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1998;33:1175–80.

    CrossRef  Google Scholar 

  43. Clark WF, Steart AK, Rock GA. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;132:777–84.

    Google Scholar 

  44. Hutchinson CA, Bradwell AR, Cook M. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745–54.

    CrossRef  Google Scholar 

  45. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone as initial therapy for multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115:1343.

    PubMed  CrossRef  CAS  Google Scholar 

  46. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated multiple myeloma. Br J Haematol. 2005;129:776.

    PubMed  CrossRef  CAS  Google Scholar 

  47. Knudsen LM, Nielsen B, Gimsing P. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:22–33.

    CrossRef  Google Scholar 

  48. Lee CK, Zangari M, Barlogie B. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823–8.

    PubMed  CrossRef  CAS  Google Scholar 

  49. Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104:1428.

    PubMed  CrossRef  CAS  Google Scholar 

  50. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906.

    PubMed  CrossRef  CAS  Google Scholar 

  51. Mehta J, Cavo M, Singhal M. How I treat elderly patients with myeloma. Blood. 2010;116:2215–23.

    PubMed  CrossRef  CAS  Google Scholar 

  52. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114:5436–43.

    PubMed  CrossRef  CAS  Google Scholar 

  53. Comenzo RL. How I treat amyloidosis. Blood. 2009;114:3147–57.

    PubMed  CrossRef  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fionnuala C. Cormack M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cormack, F.C., Richard, R.E. (2013). Multiple Myeloma and the Kidney. In: Lerma, E., Rosner, M. (eds) Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4454-1_50

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4454-1_50

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4453-4

  • Online ISBN: 978-1-4614-4454-1

  • eBook Packages: MedicineMedicine (R0)